PCSK9 drug's Ph. III results show potent effects on lipids

Share this article:

Sanofi/Regeneron's highly touted PCSK9 inhibitor, alirocumab, cut LDL "bad" cholesterol by half in the ODYSSEY MONO trial. ODYSSEY MONO is the first study to report data from the 12 Phase III trials that have been initiated so far as part of the more than 23,000 patient ODYSSEY clinical trial program.

In the release, Jay Edelberg, head of the PCSK9 development and launch unit of Sanofi Group said, "We are excited with the findings from the first Phase III trial with alirocumab.  While the majority of our clinical program is investigating alirocumab in combination with lipid-lowering therapies, these monotherapy results are encouraging."

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions